New combo therapy aims to treat leukemia without harsh chemo
NCT ID NCT07313852
First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy. Both drugs target specific proteins on leukemia cells, and the goal is to achieve remission without the severe side effects of traditional chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inotuzumab and blinatumomab
- What this could lead to
- If this works, it could offer a less toxic treatment option for older or frail adults with B-ALL who cannot handle standard chemotherapy.
- What could go wrong
- This is an early-phase trial with only 26 participants, so results may not apply widely. The combination could cause serious side effects like infections or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers